• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
AAPS BPABC Community Presentation: In silico Immunogenicity Prediction for Protein and Peptide Therapeutics

AAPS BPABC Community Presentation: In silico Immunogenicity Prediction for Protein and Peptide Therapeutics

by Elena Iemma | Mar 11, 2021 | Events, Webinars

Aimee Mattei, Senior Project Manager on our Bioinformatics team, will be presenting to the AAPS BPABC(biopharmaceutical product attributes and biological consequences) Community on March 18th at 12pm ET. You’ll need to join the group to register, membership is...
EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)

EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)

by Elena Iemma | Feb 17, 2021 | News

PROVIDENCE, RI, February 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the...
FDA Webinar: Non-clinical Immunogenicity Assessment of Generic Peptide Products: Development, Validation, and Sampling

FDA Webinar: Non-clinical Immunogenicity Assessment of Generic Peptide Products: Development, Validation, and Sampling

by Elena Iemma | Jan 26, 2021 | Events, Webinars

The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s...
Providence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview

Providence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview

by Adam | Mar 20, 2020 | News

Providence biotech company working to create coronavirus vaccine by TAMARA SACHARCZYK, NBC 10 NEWS Wednesday, March 18th 2020 Find the full story here EpiVax in Providence. (WJAR) A team of local scientists are on the front lines of a global pandemic as they race...
Press Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology

Press Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology

by Adam | Mar 4, 2020 | News

PROVIDENCE, R.I., Mar. 4, 2020 – EpiVax Inc., a Rhode Island company, announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia (UGA, Athens GA) vaccine expert Ted Ross (Director, Center for Vaccines and...
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.